For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

For patients with HFPEF and other underlying comorbidities, such as diabetes or coronary artery disease, treatment with an ACE inhibitor is nonetheless beneficial. The theoretical benefits of ACE ...

Thus, semaglutide is on a trajectory to finally provide a long-awaited treatment for HFpEF patients. According to GlobalData’s Pharma Intelligence Center, there are five Phase III candidates ...

Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...

Tectonic Therapeutics Inc. (TECX) announced favorable Phase 1a topline data for its lead asset, TX45, a long-acting, potentially ...

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...

In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...

McDonagh pointed out that treatment with finerenone yielded a similar magnitude of benefit as the SGLT2 inhibitors in the aforementioned HFpEF trials. As a reflection of the trial’s time line, just 13 ...

The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...

Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) ...

Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...